Multiple Late-Breaking Data Presentations from Incyte’s Dermatology Portfolio will be Featured at the EADV 2024 Congress ...

China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) is pleased to announce that on September 24, 2024, the New Drug Application (NDA) for ...

China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on September ...

Patients with vitiligo may significantly improve the effectiveness of a commonly used light therapy — by nearly twofold— by ...

Though INCY's performance in the year so far has been good, increasing competition for Jakafi is a concern. We advise ...

Opzelura (ruxolitinib) is now the first alternative to steroid drugs for vitiligo, a chronic autoimmune disease that causes depigmentation of skin and affects around 1.5 million people in the US.

If approved, Opzelura would provide an alternative to steroid drugs currently used to treat vitiligo, a chronic autoimmune disease that causes depigmentation of skin and affects around 1.5 million ...

As Wilmington becomes a more widely acknowledged biotech hub, Incyte will have much to do with it. The biopharmaceutical company headquartered at Augustine Cutoff, an expansion of the old Wanamaker ...

The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Opzelura is under clinical development by Incyte and currently ... topical prescription therapies or when those therapies are not advisable and nonsegmental vitiligo in adult and pediatric patients 12 ...